Morningstar Investment Management LLC Sells 155,231 Shares of Kenvue Inc. $KVUE

Morningstar Investment Management LLC lessened its position in shares of Kenvue Inc. (NYSE:KVUE) by 88.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,425 shares of the company’s stock after selling 155,231 shares during the quarter. Morningstar Investment Management LLC’s holdings in Kenvue were worth $335,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in KVUE. Compound Planning Inc. bought a new position in shares of Kenvue during the 1st quarter valued at approximately $184,000. Modern Wealth Management LLC grew its holdings in shares of Kenvue by 23.0% in the first quarter. Modern Wealth Management LLC now owns 29,777 shares of the company’s stock valued at $518,000 after purchasing an additional 5,568 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in Kenvue in the first quarter worth $2,083,000. Caxton Associates LLP bought a new stake in Kenvue in the first quarter worth $57,635,000. Finally, Capula Management Ltd raised its stake in Kenvue by 137.7% during the first quarter. Capula Management Ltd now owns 2,247,472 shares of the company’s stock valued at $38,746,000 after purchasing an additional 1,301,854 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. UBS Group upped their target price on shares of Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, July 16th. Citigroup dropped their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. Barclays boosted their price objective on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Finally, Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $19.58.

Kenvue Trading Down 0.1%

KVUE stock opened at $19.25 on Monday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $22.87. The stock has a market capitalization of $36.97 billion, a price-to-earnings ratio of 22.65, a price-to-earnings-growth ratio of 1.46 and a beta of 0.47. The firm’s fifty day simple moving average is $18.38 and its two-hundred day simple moving average is $17.92.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter in the prior year, the firm posted $0.24 earnings per share. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, analysts anticipate that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.3%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is 97.65%.

Insider Activity at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.59% of the company’s stock.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.